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ABSTRACT 
Background and design. Previous studies have demonstrated that endurance exercise can 
cause an acute transient decrease in cardiac function in healthy subjects. Whether this also 
occurs in cardiac patients is unknown. We investigated the impact of prolonged single day 
and 3-day walking exercise on cardiac function and cardiac biomarkers between cardiac 
patients and healthy controls in an observational study. 
Methods. We recruited 10 cardiac patients (9 males, 1 female, 68±5 yrs) and 10 age- and sex-
matched healthy control subjects (9 males, 1 female, 68±4 yrs) to perform 30 or 40 km of 
walking exercise per day for 3 subsequent days. Cardiac function was examined using 
echocardiography and cardiac biomarkers (cardiac troponin and B-type natriuretic peptide) 
with blood samples. Data was collected before walking and directly after walking on day 1 
and 3. 
Results. Post-exercise early systolic tissue contraction velocity of the left ventricle (LV) 
(P=0.005) and global longitudinal LV strain (P=0.026) were increased in both groups 
compared to baseline. Post-exercise right ventricle peak early diastolic tissue ﬁlling velocity 
and systolic blood pressure/LV end-systolic volume ratio decreased in both groups (P=0.043 
and P=0.028), respectively). Post-exercise cardiac troponin levels increased (P=0.045) but did 
not differed across groups (P=0.60), whereas B-type natriuretic peptide levels did not change 
(P=0.43). 
Conclusion. This study suggests that stable cardiac patients are capable of performing 3 days 
of prolonged walking exercise without clinically significant acute overall deterioration in 
cardiac function or more pronounced increase in cardiac biomarkers compared to healthy 
controls. 
 
ABSTRACT WORD COUNT: 243 
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ABBREVIATIONS 
LV  left ventricle 
RV  right ventricle 
SBP  systolic blood pressure 
DBP  diastolic blood pressure 
BSA  body surface area 
LVEF  left ventricular ejection fraction 
LVEDV left ventricular end-diastolic volume 
LVIDd end-diastolic left ventricular diastolic internal diameter 
LVESV left ventricular end-systolic volume 
SBP/ESV ratio of systolic blood pressure to left ventricular end-systolic volume 
E  peak ﬂow velocity of the early rapid ﬁlling wave at the mitral leaﬂet tips 
A  peak ﬂow velocity of the late ﬁlling wave at the mitral leaﬂet tips 
Em peak annular tissue velocity during early filling  
Am  peak annular tissue velocity during late diastolic atrial contraction  
Sm  peak annular tissue velocity during systole 
TDI  tissue Doppler imaging 
cTnI  cardiac troponin I 
BNP  B-type natriuretic peptide 
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INTRODUCTION 
Cardiovascular diseases are a major health problem, associated with a large disease burden 
and high mortality rates [1]. Exercise is an important component in the prevention and 
treatment of cardiac diseases [2, 3]. More specifically, regular exercise is recommended in the 
current guidelines for the rehabilitation of cardiac patients [4, 5, 6]. Improvements in physical 
fitness are associated with reduced risks for future cardiac events and mortality in these 
patients [7, 8].  
Despite the long-term clinical benefits of an active lifestyle,[2, 3] multiple studies have 
described an acute transient decline in cardiac function after bouts of prolonged exercise in 
healthy subjects [9, 10, 11, 12]. This response has been reported for indices of systolic and 
diastolic function, in both the left ventricle (LV) and right ventricle (RV), with a recent 
suggestion that alterations in RV function may precede changes in LV function [12]. In 
addition, elevated cardiac troponin (cTn) and B-type natriuretic peptide (BNP) levels, 
biomarkers of cardiac cell injury and cardiac stretch respectively [13, 14], are also reported 
after prolonged exercise [15, 16]. To date, studies of these phenomena have typically focused 
on athletes and healthy subjects. Whether bouts of endurance exercise result in acute changes 
in cardiac function or biomarkers of cardiac damage/stretch in subjects with an a priori 
impaired cardiac function is currently unknown.  
The aim of this study was to compare the impact of single or multiple days of prolonged (>6-
h) walking exercise on cardiac function and cardiac biomarkers between cardiac patients 
diagnosed with an impaired left ventricular function and healthy age- and sex-matched 
controls. We hypothesised that exercise leads to a greater acute decline in cardiac function 
and larger elevation of cardiac biomarkers in cardiac patients compared to healthy controls, 
and that these changes are more pronounced after 3 days of prolonged walking.  
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METHODS 
Subjects 
All subjects participated in an annual walking event (Nijmegen Four Day Marches) in which 
participants walk 30 or 40 km per day on 4 consecutive days. Ten cardiac patients with left 
ventricular systolic dysfunction were recruited through an electronic questionnaire among 
participants of the Nijmegen Four Day Marches. The inclusion criteria were a clinical history 
of cardiac disease including a history of an impaired left ventricular ejection fraction (LVEF 
<55%) measured during echocardiography. After inclusion of 10 cardiac patients, we 
recruited 10 healthy age- and sex-matched controls. Subjects in the healthy control group 
were free from (a history of) cardiovascular and cerebrovascular diseases and did not use 
cardiovascular medication. Ethical approval for this study was obtained from the Independent 
Review Board Nijmegen. This study conforms with the principles outlined in the declaration 
of Helsinki. All subjects provided written informed consent prior to participation.  
 
Experimental protocol 
Prior to participation, medical records were obtained for the cardiac patients from their 
cardiologists. Data was collected at baseline (1 day before the start of the walking event), and 
directly after walking day 1 and 3 of the event. At baseline, we examined cardiac function 
using echocardiography, a blood sample for assessment of cardiac biomarkers, and 
anthropometric and blood pressure data. After finishing the walking exercise on day 1 and day 
3, we repeated cardiac ultrasound measurements within 30-minutes post-exercise. 
Furthermore, post-exercise blood samples were collected. During exercise, we continuously 
measured heart rate and the metabolic equivalents of task in all subjects.  
 
Measurements 
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At baseline, height and weight were measured to calculate body mass index (BMI) and body 
surface area (BSA) [17]. A 4-point skin fold measurement (biceps, triceps, sub-scapular, 
supra-iliac) was done to estimate body fat percentage [18]. Finally, waist circumference was 
measured midway between the lower rib margin and iliac crest, and hip circumference was 
measured at the level of widest circumference over the greater trochanters, to determine 
waist-to-hip ratio.  
 
Exercise characteristics 
Heart rate was monitored continuously during walking with a heart rate monitor (Polar 
Electro Oy, Kempele, Finland), wore around the chest. Mean heart rate during exercise was 
expressed as a percentage of the maximal predicted heart rate [19] to indicate exercise 
intensity. Walking speed was calculated from walking duration and walking distance. An 
activity monitor (SenseWear Pro3 Armband, SWA, Body Media) was used to assess the 
metabolic equivalents of task (METs) during the walking march.  
 
Echocardiographic measurements 
A comprehensive transthoracic echocardiographic examination was performed by 3 
experienced sonographers. All participants were examined by the same sonographer on the 
different test days to minimize inter-operator variability. Echocardiography was performed 
with a 1.6 to 4 MHz multi-frequency phased array probe on a portable ultrasound system 
(Vivid Q, General Electric (GE) Medical, Horten, Norway). Images of 3-5 cardiac cycles 
during end-expiration with breath-holding (avoiding Valsalva maneuver) were recorded 
digitally on a disc and analysed post-hoc with EchoPAC software (version 113, GE Medical, 
Horten, Norway). Measurements were performed according to current guidelines of the 
American Society of Echocardiography [20]. All parameters relating to cardiac structure are 
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also expressed relative to BSA. Prior to the cardiac ultrasound, subjects were given a 10-
minute supine rest after which blood pressure and heart rate were measured. 
Estimates of preload. Left ventricular end-diastolic volume (LVEDV) was determined from 
the 2-dimensional echocardiograms in the apical 4- and 2-chamber views using the biplane 
Simpson’s method. End-diastolic left ventricular diastolic internal diameter (LVIDd) was 
measured in the parasternal long axis. We determined the ratio of the peak mitral flow 
velocity during early filling (E) and peak mitral septal and lateral annular tissue velocity 
during early filling (Em), as a surrogate parameter of left atrial pressure. An average of both 
sites is presented (E/Em).  
LV systolic function. We estimated LV ejection fraction from LVEDV and LV end-systolic 
volume (LVESV) using biplane data by ((LVEDV-LVESV)/LVEDV)*100%). The ratio of 
systolic blood pressure to ESV was determined (SBP/ESV). We obtained pulsed-wave tissue 
Doppler imaging (TDI) measurements of peak systolic annular tissue velocities at the septal 
and lateral mitral annulus from apical 4 chamber images. An average of both sites is presented 
(SmLV).  
LV strain. Two-dimensional images of the apical LV 4 chamber and 3 chamber view were 
obtained. Images were optimised for speckle tracking by keeping the frame-rate between 60-
90 Hz, adjusting imaging dept and focal zone for optimal images. Images of the apical 4 
chamber view was post-processed by a single experienced reader (AvD) using EchoPAC 
software (version 113). Aortic valve closure was marked, relative to the QR beginning of the 
QRS-complex, using pulsed-wave Doppler from apical 3 chamber view. By manual end-
systolic endocardial border tracing, the region of interest was determined and adjusted to 
include the LV wall. The software calculated the average global longitudinal strain from all 
myocardial segments. Segments judged to be of poor tracking quality, also after readjustment 
of the region of interest, were excluded. 
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LV diastolic function. To examine diastolic function we measured standard LV inﬂow pulsed-
wave Doppler at the mitral leaﬂet tips. These measurements included peak ﬂow velocity of 
the early rapid ﬁlling wave (E) and peak ﬂow velocity of the late ﬁlling wave due to atrial 
contraction (A). From these parameters we calculated the E/A ratio. From TDI measurements, 
we obtained peak early diastolic mitral annular tissue velocity (EmLV), and peak late 
diastolic mitral annular tissue velocity during atrial contraction (AmLV), for the septal and 
lateral annulus. An average of both sites is presented. 
RV systolic function. Peak systolic tricuspid lateral annular tissue velocity was measured by 
placing the pulsed-wave sample in the lateral aspect of the tricuspid annulus. Care was taken 
to ensure longitudinal movement was in line with the ultrasound beam.  
RV diastolic function. Using the same approach, peak tricuspid lateral annular tissue velocities 
during early diastole (EmRV) and during atrial contraction (AmRV) were recorded as indices 
of RV diastolic function.  
 
Cardiac biomarkers 
Cardiac troponin I (cTnI) levels and BNP levels were assessed from repetitive venous blood 
samples. The samples were analysed using high-sensitive cTnI-assays (ADVIA Centaur TnI-
ultra, Siemens Healthcare diagnostics, The Hague, the Netherlands) and BNP-assays (ADVIA 
Centaur, Siemens Healthcare diagnostics, The Hague, the Netherlands). The detection limit of 
the cTnI-assay was 6 ng/L, and the coefficient of variation was 5.3% at 80 ng/L. The 
detection limit of the BNP-assay was 2 pg/mL, and the coefficient of variation was 4.7% at 
29.4 pg/mL. 
 
Statistical analysis 
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No previous study examined the impact of prolonged exercise on cardiac function in cardiac 
patients. Therefore, no data was available to perform a sample size calculation. Hence, we 
decided to include 10 cardiac patients and 10 age- and sex-matched controls in this 
explorative, observational study. Statistical analysis was done using IBM SPSS Statistics 20.0 
(IBM SPSS, IBM Corp., Armonk, NY, USA). Parameters were checked for normality using a 
Kolmogorov-Smirnov test. When parameters were not normally distributed, a non-parametric 
alternative was used. Baseline characteristics of both groups were compared with an 
independent-samples t-test. Echocardiographic variables and cardiac biomarkers were 
analyzed with a 2-way linear mixed model analysis, with ‘time’ (baseline, day 1, day 3) and 
‘group’ (cardiac patients, controls) as factors in the model. Troponin and BNP data underwent 
natural logarithmic transformation before analysis. Due to the presence of values of zero, to 
which natural logarithmic transformation cannot be applied, all troponin and BNP data were 
increased with the value 1 before natural logarithmic transformation was performed. 
Continuous variables are presented as mean ± standard deviation (SD), unless stated 
otherwise. Significance level was set at P<0.05. 
 
 
RESULTS 
Subject characteristics 
Age, sex, body characteristics, baseline blood pressure and resting heart rate were not 
different between groups (Table 1). Medication use of the cardiac patients included: beta-
blockers (9/10), diuretics (6/10), statins (5/10), angiotensin converting enzyme inhibitors 
(6/10), antiplatelet drugs (4/10), angiotensin II receptor antagonists (3/10), coumarin 
derivatives (4/10), and anti-arrhythmic drugs (1/10). Three of the 6 patients that used diuretics 
did not use this medication during the days of exercise. Control subjects did not use 
medication. Aetiology of the cardiac disease was ischaemic heart disease (5/10, myocardial 
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infarction (n=3) or coronary artery disease (n=2)), idiopathic dilated cardiomyopathy (3/10) 
and severe mitral valve insufficiency (1/10), and multi-factorial (1/10, ischemic heart disease 
and mitral valve insufficiency). Some patients reported an intra-cardiac device (6/10). Six 
patients were classified by their cardiologist with heart failure. Cardiac patients walked 5±5 
hours a week, performed 12±17 hours per week of household activities and exercised for 4±4 
hours a week. Control subjects walked 5±6 hours per week, performed household activities 
for 18±15 hours a week and exercised for 4±3 hours a week. All habitual physical activity 
parameters did not differ between groups (p>0.05). 
 
Exercise characteristics 
All subjects completed the walking event. In both groups, 8 subjects walked 30 km/day and 2 
subjects walked 40 km/day. Controls reported a higher absolute and relative heart rate during 
exercise, whilst walking duration, walking speed and METs were comparable between groups 
(Table 2).  
 
Cardiac functionAll subjects were in normal sinus rhythm as determined by the monitoring 
ECG inherent to the ultrasound machine. Post-exercise heart rate was higher compared to 
baseline in both groups (P=0.001, Table 3). Both groups demonstrated a significantly lower 
systolic (SBP) and diastolic blood pressure (DBP) after exercise compared to baseline (SBP: 
P<0.001; DBP: P=0.001; Table 3). SmLV increased post-exercise to the same extent in both 
groups (P=0.005, Table 3). We observed a significant improvement in global longitudinal LV 
strain after day 1, but not after day 3, in both patients and controls (P=0.026, Table 3). After 
repeated exercise, SBP/ESV ratio decreased in both groups (P=0.028, Table 3). Exercise 
resulted in a decrease in EmRV after walking day 3 for both groups (P=0.043, Table 3).  
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Cardiac biomarkers 
Cardiac patients reported higher cTnI and BNP levels compared to controls at baseline and 
post-exercise on day 1, 2 and 3. Prolonged walking resulted in a significant increase in cTnI 
levels in both groups (P=0.045, Figure 1A). Prolonged walking did not change BNP levels in 
both groups (Figure 1B).  
 
 
DISCUSSION 
To our knowledge, this is the first study to investigate the effects of single and/or repeated 
exercise on cardiac function in cardiac patients compared to healthy age- and sex-matched 
controls. We report a number of novel observations. First, we demonstrate that single or 
repeated walking exercise does not impair LVEF or LV strain, whilst a small decrease in 
SBP/ESV ratio and RV diastolic filling is observed after 3 days of walking. Secondly, 
exercise induced a significant increase in cTnI, but not BNP, after walking. Most importantly, 
we found that cardiac patients and healthy controls demonstrate comparable exercise-induced 
changes when exploring the acute impact of prolonged walking exercise on cardiac function 
and cardiac biomarkers. These data emphasise that cardiac patients are well capable of 
performing strenuous, prolonged walking exercise, even when performed repeatedly (i.e. 3 
consecutive days), without evidence for a larger impact on cardiac function or cardiac 
biomarkers compared to their healthy peers.  
 
A post-exercise decrease in LV function in healthy volunteers after prolonged, strenuous 
exercise is reported in previous studies [9, 10, 11]. Moreover, Middleton et al. demonstrated a 
cumulative decrement in LV systolic function after repeated running exercise [21]. Although 
the post-exercise decrease in SBP/ESV ratio suggests a decrease in contractility, we found no 
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decrease in LVEF after 1 day or 3 days of walking 30-40 km. Moreover, we demonstrated a 
small increase in other parameters of LV systolic function (i.e. LV strain and SmLV) as 
previously described [22]. Therefore, we found no evidence of an overall decline in LV 
function after exercise. Heart rate was higher after exercise compared to baseline levels, 
which may have influenced cardiac function parameters. However, a previous animal study 
demonstrated that a higher heart rate does not lead to an increase in longitudinal strain [23], 
accordingly, we believe that the increased heart rate after exercise in our study does not 
importantly influence our outcome measures. The absence of an exercise-induced decrease in 
overall LV function might relate to the relatively low intensity of walking exercise (54-68% 
of maximal estimated heart rate), as most previous studies included exercise with higher 
intensity such as long-distance running (84% of maximal heart rate [21]) or cycling (71-76% 
of maximal heart rate [24]).  
 
The absence of a change in LV function in our study was seen in controls as well as cardiac 
patients. This indicates that an a priori impairment in LV function does not necessarily relate 
to an exercise-induced change in LV function. An explanation for the comparable exercise-
induced changes in cardiac patients and controls may relate to the comparable training status 
(control: 575±711 versus cardiac patients: 699±687 walking kilometers in the previous year, 
P=0.57) and similar exercise duration of the two groups (control: 7±2h versus cardiac 
patients: 8±1h, P=0.60). These factors, training status and exercise duration, have previously 
been associated with a decrease in LV systolic function after exercise [11]. Taken together, 
we reject our hypothesis as data from this study show that an a priori impaired LV function is 
not associated with a (larger) decrease in LV function after prolonged walking exercise.  
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Due to a relatively large increase in RV afterload during exercise, the hemodynamic demand 
placed on the RV is larger than the demand placed on the LV [12]. Indeed, some studies 
indicate that the RV function is more prone to (early) exercise-induced changes, and these 
RV-changes may precede changes in LV function [25, 26]. Whilst we demonstrated a small 
decrease in RV diastolic function, similar to previous literature [27], it was only observed 
after 3 days of prolonged walking exercise. This suggests the presence of a small but 
statistically significant cumulative effect of exercise on RV diastolic function. However, not 
all RV indices were diminished, as we did not find a decrease in RV systolic function. These 
findings can be related to the relatively low exercise intensity and corresponding smaller 
increase in heart rate and blood pressure during walking exercise compared to running or 
cycling activities like performed in previous work [25, 26]. Our study thus confirms earlier 
reports in healthy volunteers of a small decrease in RV diastolic function after prolonged 
exercise [27], whilst RV systolic function remains unaffected.  
 
An increase in cTnI after prolonged walking exercise was seen in both of our groups. The 
exercise-induced increase in cTnI in our study was not accompanied by an increase in BNP. 
Previously, it has been suggested that patients with cardiovascular diseases or associated risk 
factors are more likely to demonstrate an increase in cTnI in response to prolonged exercise 
[28, 29]. Although baseline cTnI and BNP levels were higher in cardiac patients, the relative 
change after exercise was not different between our patients and controls. A factor 
contributing to this finding might be the similar exercise intensity (measured in METs and 
walking speed) and exercise duration in cardiac patients and controls, considering that these 
are important parameters in exercise-induced biomarker release [30, 31]. Since the exercise-
induced increase in cTnI is not accompanied by significant changes in cardiac function, we 
suggest that the changes in cTnI most likely does not reflect considerable cardiac damage, 
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which is also in line with the current theory on exercise-induced increase in troponin levels 
[32].  
 
Clinical relevance. Absence of impairment in cardiac function in cardiac patients after 
exercise is clinically relevant as lifelong, regular (3-5 times a week) physical activity, in 
various forms, represents a cornerstone of contemporary cardiac rehabilitation [4, 5, 33]. 
Moreover, regular exercise at moderate-intensity, such as walking, is recommended in recent 
guidelines for cardiac patients [5, 33]. Since exercise is recommended for cardiac patients, it 
is not uncommon for these patients to participate in exercise events such as walking marches. 
Characteristic in these marches is that exercise is performed for several hours and, often, on 
consecutive days. Our observations suggest that walking exercise represents a safe type of 
exercise, even when performed for multiple hours and on consecutive days, and is not related 
to a significant impairment in cardiac function or excessive biomarker response. 
 
Limitations. The number of participants in this study was small and heterogeneous in etiology 
of heart disease. This may increase the chance for statistical errors and influences the 
generalizability of the results of this study. Moreover, due to the lack of previous data on 
cardiac function after endurance exercise in cardiac patients, a sound sample size calculation 
could not be performed. Therefore, this study should be considered as a pilot-study that may 
be a base for future studies. Participants of this study were recruited through self-administered 
questionnaires. Whilst in the patient group the medical history was confirmed through records 
of their cardiologists, we did not exclude the presence of cardiovascular disease in control 
subjects. Therefore, it is possible that the controls had some degree of (latent or silent) 
cardiovascular disease. Moreover, cardiac patients included in this study do not represent the 
general cardiac patient population as they were (highly) physically active and capable of 
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performing prolonged walking exercise. Therefore, extrapolation of our results to all cardiac 
patients is difficult. Also, we should be cautious in extrapolating our results towards the 
(long-term) safety of prolonged walking exercise in cardiac patients. Furthermore, we were 
not able to measure pulmonary artery pressure during or after exercise. Exercise increases 
pulmonary artery pressure and hereby the right ventricular afterload, and this can have a 
significant effect on right ventricular function [12]. It is possible that the pulmonary artery 
pressure will rise more significantly during exercise in patients with a priori attenuated left 
ventricle function. Future studies might further address this issue in healthy subjects and 
cardiac patients. Finally, some of the medication used by the patients affects the cardiac 
response to exercise, such as the use of β-blockers that attenuate heart rate during exercise. 
This explains that cardiac patients, whilst performing exercise at similar intensity (i.e. walking 
speed and METs), demonstrate a lower heart rate during exercise. Moreover, angiotensin 
converting enzymes inhibitors may affect blood pressure response to exercise. Nonetheless, 
we believe that our design to continue this medication is clinically relevant as this represent 
the normal situation for these patients. Furthermore, as parameters of preload demonstrate 
similar changes after exercise between cardiac patients and controls, we believe medication 
use of the patients did not alter the main findings of our study.   
 
Conclusion. Repeated prolonged walking exercise did not significantly impair overall cardiac 
function in cardiac patients or controls directly after exercise. Both groups demonstrated a 
subclinical decrease in left ventricular contractility and right ventricular early diastolic filling 
and an increase in cTnI levels after repeated bouts of exercise, without having significant 
negative consequences for the LVEF and LV strain. Interestingly, these findings were 
similarly present in both groups. This suggests that stable cardiac patients are capable of 
performing (3 days of) prolonged walking exercise without a significant overall acute 
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deterioration in cardiac function or a more pronounced release of cardiac biomarkers 
compared to controls. 
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FIGURE LEGENDS 
 
 
 
Figure 1. cTnI levels (A) and BNP levels (B) before exercise (baseline) and immediately 
post-exercise on day 1, day 2 and day 3 for controls (white circles) and cardiac patients (black 
squares). P-values refer to a linear mixed model analysis to examine whether changes in 
biomarkers across the 3 testing days (‘Time’) differs between groups (‘Group’, 
‘Time*Group’). Error bars represent SE. *cTnI levels significantly increased compared to 
baseline. 
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TABLE 1 
Table 1. Subject characteristics and cardiovascular medication use of healthy controls (n=10) and cardiac 
patients (n=10) at baseline. Data is presented as mean±SD. P-values refer to an independent-samples t-test. 
 Controls  Cardiac patients P-value 
Subject characteristics    
Age (yrs) 68±4 68±5 0.92 
Sex (male:female) 9:1 9:1 - 
Weight (kg) 82±14 81±13 0.78 
BMI (kg/m2) 25.6±3.2 26.2±4.0 0.75 
BSA (m2) 2.01±0.18 1.96±0.17 0.56 
Waist circumference (cm) 97±12 96±13 0.93 
Hip circumference (cm) 100±6 99±6 0.69 
Waist-to-hip ratio# 0.96±0.07 0.97±0.09 0.65 
Fat percentage (%) 30±6 32±5 0.39 
Resting SBP (mmHg) 140±13 126±19 0.09 
Resting DBP (mmHg) 80±7 75±9 0.16 
Resting heart rate (beats/min) 64±9 57±8 0.09 
Total training kilometres (km)# 575±711 699±687 0.57 
#P-value relate to Mann-Whitney U test. Data on total training kilometers was missing for 1 cardiac patient. 
BMI; body mass index. BSA; body surface area. SBP; systolic blood pressure. DBP; diastolic blood pressure.  
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Table 2. Exercise characteristics of healthy controls (n=10) and cardiac patients (n=10) on the 3 walking days. P-values refer to a linear mixed 
model analysis that examined whether exercise parameters were different across the 3 walking days (‘Time’) or between groups (‘Group’), and 
whether a different change across the 3 walking days was present between controls and cardiac patients (‘Time*Group’). Data are presented as 
mean±SD. 
 Controls Cardiac patients P-value 
Day1 Day2 Day 3 Day1 Day2 Day 3 Time Group Time*Group 
Duration (min) 424±91 470±114* 416±111 451±55 474±54* 442±66 0.001 0.60 0.50 
Mean heart rate (/min)# 109±23 108±28 109±27 91±14 88±13 87±9 0.16 <0.001 0.45 
Mean heart rate %max 
(%)# 
68±14 68±17 68±16 57±8 55±7 54±5 0.16 <0.001 0.46 
MET 5.2±1.0 4.4±0.5* 4.6±0.6* 5.4±0.5 4.8±0.5* 4.7±0.5* <0.001 0.52 0.60 
Walking speed (km/h) 4.7±0.9 4.1±1.0* 4.8±1.0 4.3±0.6 4.1±0.5* 4.4±0.6 0.002 0.35 0.44 
*Significantly different compared to day 1. #A non-parametric alternative was used to perform the analysis: a Friedman test for the time-effect, 
a Mann-Whitney test for the group effect, and a repeated measures ANOVA on the delta’s of day 2 and day 3 compared to day 1. MET; 
metabolic equivalent of task. 
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TABLE 3 
Table 3. Cardiac function and structure of healthy controls (n=10) and cardiac patients (n=10) at baseline and immediately after exercise on day 1 and day 3. P-values refer to a 
linear mixed model analysis that examined whether cardiac function and structure were different from baseline across the 3 walking days (‘Time’) or between groups (‘Group’), 
and whether a different change across the 3 walking days was present between controls and cardiac patients (‘Time*Group’). Data are presented as mean±SD. 
 
Preload 
Controls Cardiac patients P-value 
Pre Day 1 Day 3 Pre Day 1 Day 3 Time Group Time*Group 
Heart rate (/min) 65±8† 70±14* 77±12* 58±8 63±13* 64±11* 0.001 0.037 0.35 
SBP (mmHg) 141±13† 128±9* 130±10* 126±19 110±14* 110±17* <0.001 0.004 0.70 
DBP (mmHg) 81±7† 75±9* 76±6* 75±9 65±8* 65±5* 0.001 0.002 0.43 
LVEDV (mL) 97±19† 99±20 99±9 141±33 123±23 123±29 0.31 0.003 0.15 
LVIDd (cm)# 4.4±2 4.5±0.6 4.7±0.5 5.4±0.6 5.3±0.4 5.3±0.6 0.40 <0.001 0.57 
E/Em# 8.1±2.7 7.2±2.2 6.5±2.1 9.8±5.7 9.8±5.9 9.2±6.5 0.37 0.27 0.82 
LV systolic function          
LVEF, biplane (%) 60±10† 56±9 55±6 48±10 46±12 42±10 0.06 0.008 0.91 
LV strain (%) -20±3† -21±3* -19±3 -13±3 -16±4* -14±3 0.026 <0.001 0.053 
SmLV (m/s) 0.08±0.01 0.09±0.02* 0.09±0.02* 0.07±0.01 0.08±0.02* 0.08±0.02* 0.005 0.08 0.66 
LVESV (mL) 42±13† 40±16 44±9 74±28 65±22 73±16 0.19 0.002 0.63 
SBP/ESV 3.62±0.95† 3.28±1.20 3.02±0.57* 1.88±0.55 1.88±0.69 1.55±0.32* 0.028 <0.001 0.64 
LV diastolic function          
E (m/s) 0.59±0.17 0.49±0.11 0.51±0.14 0.61±027 0.59±0.20 0.59±0.20 0.06 0.31 0.82 
A (m/s) 0.66±0.13 0.65±0.13 0.65±0.10 0.74±0.32 0.71±0.27 0.77±0.29 0.34 0.34 0.48 
E/A  0.87±0.12 0.76±0.08 0.77±0.11 0.86±0.29 0.85±0.22 0.77±0.13 0.12 0.58 0.33 
EmLV (m/s) 0.08±0.02 0.08±0.01 0.08±0.02 0.07±0.02 0.07±0.02 0.07±0.02 0.73 0.43 0.73 
AmLV (m/s)# 0.09±0.01 0.10±0.02 0.10±0.02 0.09±0.01 0.09±0.03 0.09±0.01 0.55 0.22 0.54 
RV systolic function          
SmRV (m/s) 0.13±0.02† 0.13±0.03 0.14±0.04 0.10±0.03 0.10±0.03 0.10±0.03 0.17 0.014 0.71 
RV diastolic function          
EmRV (m/s)# 0.10±0.04† 0.09±0.03 0.08±0.02* 0.08±0.02 0.08±0.03 0.06±0.02* 0.043 0.006 0.56 
AmRV(m/s)# 0.14±0.05 0.16±0.06 0.16±0.05 0.10±0.04 0.12±0.04 0.11±0.04 0.13 0.001 0.53 
#A non-parametric alternative was used to perform the analysis: a Friedman test for the time-effect, a Mann-Whitney test for the group effect, and a repeated measures ANOVA on 
the delta’s of day 1 and day 3 compared to baseline. *significantly different compared to baseline (pre). †significantly different compared to cardiac patients at baseline. SBP; 
systolic blood pressure. DBP; diastolic blood pressure. LVEDV; left ventricular end-diastolic volume. LVIDd: left ventricular internal diameter end-diastole; E; peak ﬂow velocity 
of the early rapid ﬁlling wave at the mitral leaﬂet tips. Em; peak annular tissue velocity during early filling. LVEF; left ventricular ejection fraction. LV; left ventricle. RV; right 
ventricle. Sm; peak annular tissue velocity during systole. LVESV; left ventricular end-systolic volume. SBP/ESV; ratio between systolic blood pressure and end-systolic volume 
of the left ventricule; A; peak ﬂow velocity of the late ﬁlling wave at the mitral leaﬂet tips. Am; peak annular tissue velocity during late diastolic atrial contraction. 
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Supplementary table 
Supplementary table. Cardiac function and structure of healthy controls (n=10) and cardiac patients (n=10) at baseline and immediately after exercise on day 1 and day 3. P-
values refer to a linear mixed model analysis that examined whether cardiac function and structure were different from baseline across the 3 walking days (‘Time’) or between 
groups (‘Group’), and whether a different change across the 3 walking days was present between controls and cardiac patients (‘Time*Group’). All parameters are expressed 
relative to body surface area (BSA, m2). Data are presented as mean±SD. 
 
Preload 
Controls Cardiac patients P-value 
Pre Day 1 Day 3 Pre Day 1 Day 3 Time Group Time*Group 
LVEDV (mL/m2) 49±8† 50±10 51±5 73±20 63±15 64±18 0.32 0.009 0.11 
LVIDd (cm/m2)# 2.2±0.9 2.3±0.4 2.3±0.3 2.8±0.4 2.7±0.3 2.7±0.4 0.40 0.001 0.57 
LV systolic function          
LVESV (mL/m2) 21±6† 20±8 22±5 38±17 34±13 38±9 0.20 0.003 0.60 
#A non-parametric alternative was used to perform the analysis: a Friedman test for the time-effect, a Mann-Whitney test for the group effect, and a repeated measures ANOVA on 
the delta’s of day 1 and day 3 compared to baseline. *significantly different compared to baseline (pre). †significantly different compared to cardiac patients at baseline. SBP; 
systolic blood pressure. DBP; diastolic blood pressure. LVEDV; left ventricular end-diastolic volume. LVIDd: left ventricular internal diameter end-diastole; LVESV; left 
ventricular end-systolic volume.  
 
 
 
 
 
 
